Literature DB >> 26982740

Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.

Kiyanna Williams1, Sarah T Arron2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26982740     DOI: 10.1001/jamadermatol.2016.0351

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Authors:  B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2017-04-18       Impact factor: 6.875

3.  Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation.

Authors:  Lawrence F Kuklinski; Shufeng Li; Margaret R Karagas; Wen-Kai Weng; Bernice Y Kwong
Journal:  J Am Acad Dermatol       Date:  2017-08-02       Impact factor: 11.527

Review 4.  Cutaneous Squamous Cell Carcinoma Arising in Immunosuppressed Patients: A Systematic Review of Tumor Profiling Studies.

Authors:  Elliot D Blue; S Caleb Freeman; Marissa B Lobl; Dillon D Clarey; Rose L Fredrick; Ashley Wysong; Melodi Javid Whitley
Journal:  JID Innov       Date:  2022-03-30

5.  Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?

Authors:  Matthew A Miller; Yee Ming Lee
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.